Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases ...
Data include a concurrent assessment of results collected from PGI and AMRA instruments, insights into clinically meaningful changes in HAE attack symptoms, and support for hierarchical ranking of ...
RAPIDe-3 met the primary and all 11 secondary efficacy endpoints with high statistical significance with deucrictibant achieving onset of symptom relief in 1.28 hours and complete symptom resolution ...
New interim data from the KONFIDENT-KID trial evaluating sebetralstat in children aged 2-11 accepted for late-breaking oral presentation FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS ...
BW-20805 works by suppressing hepatic plasma prekallikrein expression to prevent excessive bradykinin generation and reduce the potential for HAE attacks. The Food and Drug Administration (FDA) has ...
An update from Pharvaris ( (PHVS) ) is now available.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results